Antiangiogenesis: a possible treatment option for prostate cancer?
Antiangiogenesis: a possible treatment option for prostate cancer?
复制标题
DOI：
10.3816/cgc.2005.n.033
复制
发表时间：
2005-12-01
影响因子：
3.2
通讯作者：
Figg, William D
中科院分区：
文献类型：
--
作者：
Longoria, Ritchie L;Cox, Michael C;Figg, William D
随着对前列腺癌有效治疗方式的需求，血管生成是干扰肿瘤进展的可能靶点。血管生成促进肿瘤的脉管系统，允许肿瘤进展和癌细胞转移并扩散到整个循环系统。迄今为止，有> 20种抗血管生成药物正在单独进行临床前和临床研究，以及与其他治疗方案联合进行临床前和临床研究，以确定抗血管生成药物在前列腺癌治疗中的有效性。本文综述了抗血管生成的几个方面及其与前列腺癌治疗的关系。
With a need for effective treatment modalities in prostate cancer, angiogenesis is a likely target for the interference of tumor progression. Angiogenesis promotes the vasculature of a tumor, allowing for tumor progression and for cancer cells to metastasize and spread throughout the circulatory system. To date, there are > 20 antiangiogenic drugs undergoing preclinical and clinical investigation alone and in conjunction with other treatment options to determine the validity of antiangiogenic agents in the treatment of prostate cancer. This article reviews several aspects of antiangiogenesis and its relationship to the treatment of prostate cancer.